Paclitaxel drug-coated balloons and drug-eluting stents

AI Summary

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued updated clinical guidance regarding the use of paclitaxel-coated devices (PCD) for treating peripheral arterial disease (PAD). Following a review of mortality data by the Expert Advisory Group (EAG), the MHRA recommends that these devices should no longer be used to treat patients with intermittent claudication due to the availability of safer alternatives. For patients with critical limb ischaemia, PCDs may still be considered if the clinical benefits outweigh the risks, in accordance with NICE guidelines. The regulatory framework emphasizes patient safety and data transparency. Required actions include establishing enhanced follow-up protocols for all patients receiving these implants. Furthermore, the MHRA mandates reporting of any adverse events through the Yellow Card scheme for patients or national reporting systems for healthcare professionals in England, Scotland, Wales, and Northern Ireland. While this document does not cite a specific company or inspection date, it represents a formal safety update published in February 2024 under reference DSI/2024/001. This directive ensures that the use of paclitaxel-coated technology is limited to high-risk cases where clinical necessity is clearly demonstrated.